Top

Published in:

01-08-2015 | Original Paper

Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study

Authors: Fabian aus dem Siepen, Sebastian J. Buss, Florian Andre, Sebastian Seitz, Evangelos Giannitsis, Henning Steen, Hugo A. Katus, Arnt V. Kristen

Published in: Clinical Research in Cardiology | Issue 8/2015

Abstract

Objectives

T1 mapping by cardiac magnetic resonance imaging (CMR) is able to determine the extracellular volume fraction. Wild-type transthyretin amyloidosis (WT-ATTR) is characterized by extracellular amyloid deposition in the heart. Recent reports indicated a reduction of left ventricular (LV) myocardial mass in WT-ATTR after consumption of epigallocatechin-3-gallate, the main catechin in green tea. It remained unclear, whether reduction of LV myocardial mass reflects decrease of amyloid load or progressive atrophy of cardiomyocytes.

Methods

This study included 7 male patients with CMR repetitively performed before and 12 months after daily consumption of green tea extract (600 mg epigallocatechin-3-gallate). Short axis slices as well as 2-, 3-, and 4-chamber views were acquired using SSFP sequences. T1 mapping was created out of 11 mid-ventricular short axis views with increasing inversion times using a single breath-hold modified look-locker inversion recovery sequence before and 15 min after Gadolinium contrast administration.

Results

After 12 months, a significant decrease of LV myocardial mass [198 (160; 212) vs. 180 (142; 204) g; p < 0.05] was observed. Moreover, a significant decrease of native [T1 1110 (1072; 1150) ms vs. 1080 (970; 1101), p < 0.05 or p = 0.03] was noticed. The calculated extracellular volume decreased in 5 patients (62.5 %) by 7 % and increased in 2 patients (37.5 %) by 9.5 %, in trend resulting in a (not significant) decrease of median ECV by 2.4 %. Left ventricular ejection fraction (LVEF) [57 (48; 65) vs. 55 (47; 64) %; p = 0.3] remained unchanged.

Conclusions

This study provided further evidence of LV myocardial mass reduction in patients with WT-ATTR daily consuming green tea extract. Additionally, this study gave first insights into the histomorphological correlate of LV mass reduction using T1 mapping. LV mass reduction appeared to be rather due to a decrease of amyloid load than atrophy of cardiomyocytes.

Available only for authorised users

Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618–623PubMedCrossRef

Pomerance A (1965) Senile cardiac amyloidosis. Br Heart J 27(5):711–718PubMedCentralPubMedCrossRef

Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A (2013) Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 106(10):528–540. doi:10.1016/j.acvd.2013.06.051 PubMedCrossRef

Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109(24):9629–9634. doi:10.1073/pnas.1121005109 PubMedCentralPubMedCrossRef

Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792. doi:10.1212/WNL.0b013e3182661eb1 PubMedCentralPubMedCrossRef

Nencetti S, Rossello A, Orlandini E (2013) Tafamidis (Vyndaqel): a light for FAP patients. Chem Med Chem. doi:10.1002/cmdc.201300245 PubMed

Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107(17):7710–7715. doi:10.1073/pnas.0910723107 PubMedCentralPubMedCrossRef

Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15(6):558–566. doi:10.1038/nsmb.1437 PubMedCrossRef

Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Bai G, Saraiva MJ, Almeida MR (2009) Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 583(22):3569–3576. doi:10.1016/j.febslet.2009.10.062 PubMedCrossRef

10.

Ferreira N, Saraiva MJ, Almeida MR (2012) Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice models. PLoS One 7(1):e29933. doi:10.1371/journal.pone.0029933 PubMedCentralPubMedCrossRef

11.

Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Rocken C, Wanker EE, Dengler TJ, Altland K, Katus HA (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 101(10):805–813. doi:10.1007/s00392-012-0463-z PubMedCentralPubMedCrossRef

12.

White SK, Sado DM, Flett AS, Moon JC (2012) Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart 98(10):773–779. doi:10.1136/heartjnl-2011-301515 PubMedCrossRef

13.

Jerosch-Herold M, Kwong RY (2014) Cardiac T(1) imaging. Top Magn Reson Imaging 23(1):3–11. doi:10.1097/RMR.0000000000000013 PubMedCrossRef

14.

Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB (2013) Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 15:92. doi:10.1186/1532-429X-15-92 PubMedCentralPubMedCrossRef

15.

Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, Potena L, Leone O, Bartolomei I, Pastorelli F, Salvi F, Rapezzi C (2014) Identification of TTR-related subclinical amyloidosis with (99 m)Tc-DPD scintigraphy. JACC Cardiovasc Imaging 7(5):531–532. doi:10.1016/j.jcmg.2014.03.004 PubMedCrossRef

16.

Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528. doi:10.1093/eurheartj/ehs123 PubMedCrossRef

17.

Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165(12):1425–1429. doi:10.1001/archinte.165.12.1425 PubMedCrossRef

18.

Benson MD, Teague SD, Kovacs R, Feigenbaum H, Jung J, Kincaid JC (2011) Rate of progression of transthyretin amyloidosis. Am J Cardiol 108(2):285–289. doi:10.1016/j.amjcard.2011.03.040 PubMedCrossRef

19.

Ruberg FL, Maurer, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS). Am Heart J 164(2):222–228e221. doi:10.1016/j.ahj.2012.04.015 PubMedCrossRef

20.

Hunstein W (2007) Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110(6):2216. doi:10.1182/blood-2007-05-089243 PubMedCrossRef

21.

Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99(8):483–490. doi:10.1007/s00392-010-0142-x PubMedCrossRef

22.

Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovas Imaging 7(2):157–165. doi:10.1016/j.jcmg.2013.10.008 CrossRef

23.

Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE (2008) Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 295(3):H1234–H1242. doi:10.1152/ajpheart.00429.2008 PubMedCentralPubMedCrossRef

24.

Kehr E, Sono M, Chugh SS, Jerosch-Herold M (2008) Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro. Int J Cardiovasc Imaging 24(1):61–68. doi:10.1007/s10554-007-9223-y PubMedCrossRef

25.

Pack NA, Dibella EV, Wilson BD, McGann CJ (2008) Quantitative myocardial distribution volume from dynamic contrast-enhanced MRI. Magn Reson Imaging 26(4):532–542. doi:10.1016/j.mri.2007.10.003 PubMedCentralPubMedCrossRef

26.

Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovascular Imaging 6(4):488–497. doi:10.1016/j.jcmg.2012.11.013 PubMedCrossRef

27.

Brooks J, Kramer CM, Salerno M (2013) Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mapping. J Magn Reson Imaging 38(6):1591–1595. doi:10.1002/jmri.24078 PubMedCrossRef

28.

Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54. doi:10.1186/1532-429X-10-54 PubMedCentralPubMedCrossRef

29.

Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC (2010) Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122(2):138–144. doi:10.1161/CIRCULATIONAHA.109.930636 PubMedCrossRef

30.

Kuruvilla S, Janardhanan R, Antkowiak P, Keeley EC, Adenaw N, Brooks J, Epstein FH, Kramer CM, Salerno M (2014) Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging. doi:10.1016/j.jcmg.2014.09.020

31.

Sado DM, Maestrini V, Piechnik SK, Banypersad SM, White SK, Flett AS, Robson MD, Neubauer S, Ariti C, Arai A, Kellman P, Yamamura J, Schoennagel BP, Shah F, Davis B, Trompeter S, Walker M, Porter J, Moon JC (2014) Noncontrast myocardial T mapping using cardiovascular magnetic resonance for iron overload. J Magn Reson Imaging. doi:10.1002/jmri.24727 PubMed

32.

Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, Pastor A, Carr-White G, Razavi R, Schaeffter T, Nagel E (2013) Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 6(4):475–484. doi:10.1016/j.jcmg.2012.08.019 PubMedCrossRef

Title: Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study
Authors: Fabian aus dem Siepen
Sebastian J. Buss
Florian Andre
Sebastian Seitz
Evangelos Giannitsis
Henning Steen
Hugo A. Katus
Arnt V. Kristen
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 8/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-015-0826-3

2024 ASCO Annual Meeting

Springer Medicine

Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study

Abstract

Objectives

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2015

Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons

Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation

Prevalence and impact on outcome of electrocardiographic early repolarization patterns among stroke patients: a prospective observational study

Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension

Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy

Acute coronary syndrome in young women under 55 years of age: clinical characteristics, treatment, and outcomes